Scholars Central

OtherPublished 27 Jul 2016

Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders

Authors: Anurag Agrawal, Peter Whorwell

Clinical Practice

Volume 3 · Issue 4 · Pages 475

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Irritable bowel syndrome is a common condition for which, until recently, treatment options have been limited. Tegaserod has selective serotonin subtype 4 receptor agonist activity and acts by increasing gastrointestinal motility, secretion and possibly reducing visceral sensitivity. It has been developed to treat patients with irritable bowel syndrome who suffer from abdominal pain, constipation and bloating. Studies so far suggest that it is an effective treatment for these symptoms with an excellent safety profile. Its role in other functional gastrointestinal disorders, such as functional dyspepsia, is still being assessed. This review describes the structure, pharmacokinetic and pharmacodynamic properties of tegaserod and its effect on gastrointestinal physiology, as well as its clinical utility.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Anurag Agrawal”
  • BylineArticles whose byline prints “Peter Whorwell”